Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuya Murase

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2025
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational studyYuichi Tambo, Takashi Sone, Koichi Nishi, et al.
Cancer Science|November 9, 2025
MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular ToxicityShigeki Sato, Neval Yilmaz, Sachiko Arai, et al.
Lung Cancer (Amsterdam, Netherlands)|January 17, 2026
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancerYuya Murase, Hayato Koba, Hideharu Kimura, et al.
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
Cancer Science|January 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive CancersYuya Murase, Shigeki Nanjo, Sachiko Arai, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2025
Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational studyYuichi Tambo, Takashi Sone, Koichi Nishi, et al.
Cancer Science|November 9, 2025
MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular ToxicityShigeki Sato, Neval Yilmaz, Sachiko Arai, et al.
Lung Cancer (Amsterdam, Netherlands)|January 17, 2026
Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancerYuya Murase, Hayato Koba, Hideharu Kimura, et al.
Oncogene|July 2, 2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancerYifeng Liu, Shigeki Nanjo, Yuya Murase, et al.
Cancer Science|January 18, 2026
Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive CancersYuya Murase, Shigeki Nanjo, Sachiko Arai, et al.
Pageof 2